Evidence map›Paper›PMID 41283237›Full record

ArticleHematology reports2025

PD-1 Expression Promotes Immune Evasion in B-ALL.

Ana Casado-García, Gonzalo García-Aguilera, Julio Pozo, Ninad Oak, Susana Barrena, Belén Ruiz-Corzo, Jaanam Lalchandani, Ana Chamorro-Vera, Ana Castillo-Robleda, Beatriz Soriano and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ana Casado-GarcíaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0003-1510-1499
Gonzalo García-AguileraFundación para la Investigación Biomédica del Hospital Universitario La Princesa, 28006 Madrid, Spain.
Julio PozoServicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC), CSIC/Universidad de Salamanca, 37007 Salamanca, Spain.
Ninad OakDepartment of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA.ORCID 0000-0002-9806-0217
Susana BarrenaServicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC), CSIC/Universidad de Salamanca, 37007 Salamanca, Spain.
Belén Ruiz-CorzoExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.
Jaanam LalchandaniAdvance Therapy Unit, Oncohematology Department, Fundación para la Investigación Biomédica del Hospital Infantil Universitario del Niño Jesús, Avenida Menendez y Pelayo, 65 28009 Madrid, Spain.ORCID 0009-0008-2362-8323
Ana Chamorro-VeraDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Avenida Menendez y Pelayo, 65, 28009 Madrid, Spain.
Ana Castillo-RobledaDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Avenida Menendez y Pelayo, 65, 28009 Madrid, Spain.
Beatriz SorianoServicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC), CSIC/Universidad de Salamanca, 37007 Salamanca, Spain.
Silvia Alemán-ArteagaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0002-9655-2242
Elena G SánchezAdvance Therapy Unit, Oncohematology Department, Fundación para la Investigación Biomédica del Hospital Infantil Universitario del Niño Jesús, Avenida Menendez y Pelayo, 65 28009 Madrid, Spain.
Jorge Martínez-CanoImmune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), 28049 Madrid, Spain.ORCID 0000-0001-6809-5489
Andrea López-Álvarez de NeyraExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0009-0000-0430-312X
Paula Somoza-CotillasExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.
Oscar BlancoInstituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain.
Susana RiescoInstituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain.
Pablo Prieto-MatosInstituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0003-2680-3285
Francisco Javier García CriadoInstituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain.
María Begoña García CenadorInstituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0002-8950-8542
César CobaledaImmune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), 28049 Madrid, Spain.ORCID 0000-0003-3807-9204
Carolina Vicente-DueñasInstituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0002-5401-8295
Kim E NicholsDepartment of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA.ORCID 0000-0002-5581-6555
Alberto OrfaoInstituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, Campus Miguel de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0002-0007-7230
Manuel Ramírez-OrellanaDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid, Avenida Menendez y Pelayo, 65, 28009 Madrid, Spain.ORCID 0000-0003-0332-6973
Isidro Sánchez-GarcíaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL, Campus M. de Unamuno s/n, 37007 Salamanca, Spain.ORCID 0000-0001-6989-9905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesIn children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise "silent" preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms. METHODS AND

resultsHere, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by

conclusionsThese results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.

Indexed as

acutechildhoodgenetic susceptibilityimmune evasionimmunotherapyleukemiamurine modelspreleukemic cells

Identifiers

PMID41283237
PMCPMC12641702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.